Vani Manja的动态

Exciting news! Eli Lilly is poised to "build a new way of doing science" in the UK, thanks to a ￡297m pledge to boost the nation's life sciences sector. ?? Announced at the International Investment Summit in London, this move includes launching the first European Lilly Gateway Labs—an incubator to support early-stage life science start-ups. This initiative will provide companies with access to lab space, equipment, and collaboration opportunities with Lilly scientists. It's a fantastic step forward for the UK's biotech industry! Lilly is leveraging technology like AI to revolutionise pharmaceutical product development. ?? At the BIA TechBio 2024 conference, Senior VP Ramesh Durvasula highlighted how the company is "constantly reinventing" itself using the latest tech. Alongside Lilly Gateway Labs, collaborations such as the recent partnership with insitro aim to develop treatments for metabolic diseases combining machine learning and drug delivery technology. Such initiatives not only foster innovation but also lay the foundation for the next generation of medical breakthroughs. In addition to setting up Lilly Gateway Labs, the funding will support a five-year clinical trial named SURMOUNT-REAL UK. This study will evaluate Mounjaro's effectiveness in weight loss and diabetes prevention, enhancing health outcomes for adults with obesity. Mounjaro was also recommended by NICE and will soon be accessible to those with the greatest clinical need, as per NHS England's phased rollout plan. This commitment signifies a milestone in improving health for people with obesity and related conditions. #Biotech #LifeSciences #Innovation

Exciting news! Eli Lilly is poised to "build a new way of doing science" in the UK, thanks to a ￡297m pledge to boost the nation's life sciences sector. ?? Announced at the International Investment Summit in London, this move includes launching the first European Lilly Gateway Labs—an incubator to support early-stage life science start-ups. This initiative will provide companies with access to lab space, equipment, and collaboration opportunities with Lilly scientists. It's a fantastic step forward for the UK's biotech industry! Lilly is leveraging technology like AI to revolutionise pharmaceutical product development. ?? At the BIA TechBio 2024 conference, Senior VP Ramesh Durvasula highlighted how the company is "constantly reinventing" itself using the latest tech. Alongside Lilly Gateway Labs, collaborations such as the recent partnership with insitro aim to develop treatments for metabolic diseases combining machine learning and drug delivery technology. Such initiatives not only foster innovation but also lay the foundation for the next generation of medical breakthroughs. In addition to setting up Lilly Gateway Labs, the funding will support a five-year clinical trial named SURMOUNT-REAL UK. This study will evaluate Mounjaro's effectiveness in weight loss and diabetes prevention, enhancing health outcomes for adults with obesity. Mounjaro was also recommended by NICE and will soon be accessible to those with the greatest clinical need, as per NHS England's phased rollout plan. This commitment signifies a milestone in improving health for people with obesity and related conditions. #Biotech #LifeSciences #Innovation

While new technologies and smart solutions play a pivotal role in transforming the #clinicaltrial landscape, collaboration is also a key aspect of innovation. Thermo Fisher Scientific’s newly opened Innovation Lab in Center Valley, PA is designed to foster a culture of co-creation and strategic thinking to maximize the impact of innovation and advance clinical trial research. Sarah Blake Englert, senior director of innovation and program management, shared her insights on why the lab was designed with rapid innovation in mind and how the outcomes generated from the lab are expected to have a significant impact on clinical trials – from more accessible trials for participants to getting life-saving therapies to patients, faster. Learn more in this article by Outsourcing-Pharma: https://spr.ly/6044br0kg

While new technologies and smart solutions play a pivotal role in transforming the #clinicaltrial landscape, collaboration is also a key aspect of innovation. Thermo Fisher Scientific’s newly opened Innovation Lab in Center Valley, PA is designed to foster a culture of co-creation and strategic thinking to maximize the impact of innovation and advance clinical trial research. Sarah Blake Englert, senior director of innovation and program management, shared her insights on why the lab was designed with rapid innovation in mind and how the outcomes generated from the lab are expected to have a significant impact on clinical trials – from more accessible trials for participants to getting life-saving therapies to patients, faster. Learn more in this article by Outsourcing-Pharma: https://spr.ly/6043br0k5

The RHC applauds the Ontario government and AstraZeneca for their significant investment to expand life science research and development, driving growth in Ontario’s life sciences sector. This milestone reflects Ontario’s commitment to its "Taking Life Sciences to the Next Level" strategy, reinforcing its leadership in biomanufacturing and innovation. We are proud to see investments that not only strengthen the development of cutting-edge health technologies but also create new opportunities for the life sciences workforce. The RHC remains dedicated to advancing Canada’s life sciences ecosystem, advocating for innovative solutions that improve care, access, and outcomes for patients. https://lnkd.in/eccGT2q9

Last month, I had the pleasure of speaking about "Democratising Target Discovery and Validation through Personalised Learning Journeys" at BioTechX USA 2024 in Philadelphia. ?? In today's rapidly evolving pharma landscape, digital literacy can often be overlooked in a busy workday, yet it stands as a cornerstone for breakthroughs in drug discovery. At Novo Nordisk's R&ED Digital Science Academy, we are reshaping this narrative by crafting personalised learning journeys tailored to integrate digital advancements into the everyday practice of R&ED. This challenging yet fascinating task can only be achieved through close collaboration with everyone in the line of business to understand their needs and develop appropriate training. We strive to balance promoting best practices with accommodating individual needs and skills, while maintaining the flexibility necessary for innovation. This approach ensures that we continue to innovate the next treatments for our patients. It was amazing to meet up with colleagues from Novo Nordisk and like-minded professionals from many other pharma companies, biotech firms, and academia to discuss the future of learning and digital upskilling in drug discovery. This is a major focus and apparently a daunting task ?? Looking forward to continuing this journey and seeing the tangible impacts of our efforts as part of the fantastic team at the Digital Science Academy and all our amazing colleagues in NN R&ED. #DigitalTransformation #Bioinformatics #InSilico #GenAI #LearningJourneys #NovoNordisk #BioTechXUSA #DrugDiscovery #DigitalLiteracy

? ????????????: ?? ?????? ?????? ???? ?????????????????????????? ?????? ???????????????????? ???? ???? ??????????????? ? ?? ?????? ?????????????? ???? ?????? ???????????? ???? The Francis Crick Institute ?????????? ?? ?????????????? ???????????? ?????? ???? ??????????????.?A new 11,800-square-foot specialized life sciences laboratory, developed in collaboration with MSD (Merck & Co., Inc.), is set to redefine opportunities for research and innovation. ?? ???????? ???????????????? ???????? ???????????????????? ?????? ?????????????????????? ?????????????? The Francis Crick Institute ?????? MSD, enhancing collaboration and opening new pathways for discovery science to thrive. It’s a significant step towards growing the UK’s position as a global leader in life sciences. ?? ?????? ???????????? ???????? ?????? ???????? ?????????????? ??????????????-???????? ?????? ???????????but will also contribute to MSD's expansion in the UK, with a focus on immunology, antibody development, and other breakthrough areas of research. This initiative showcases the power of public-private partnerships in driving transformative advances in healthcare and economic growth. ?? ?????? ￡???? ?????????????? ???????????????????????? ???????? ?????? ?????????? ???????????? ????????????????????, coupled with MSD’s plans to establish their new headquarters, will further accelerate scientific discovery and the translation of innovations into real-world applications. ?? ???????? ?????? ???????? ???????????????? ???? ?????? ???????????????????????? ???????? ???????? ?????? ?????????????? ?????? ???????????? ???? ???????? ???????????????? ?????? ????????????????????? ?? Follow me for more insights on how collaborations like these are paving the way for scientific breakthroughs and economic growth in the UK! https://lnkd.in/em97Dazy #LifeSciences #Innovation #PublicPrivatePartnership

? Trailblazer Spotlight: Dr. Reshma Kewalramani ? Dr. Reshma Kewalramani, MD, FASN, is transforming biotech as the CEO and President of Vertex Pharmaceuticals. A summa cum laude graduate of Boston University, she completed her medical training at Massachusetts General Hospital and Brigham and Women’s Hospital. After leading groundbreaking trials at Amgen, she joined Vertex in 2017, becoming CEO in 2020. Under her leadership, Vertex expanded cystic fibrosis treatments to reach 90% of patients and advanced therapies for sickle cell, beta thalassemia, and type 1 diabetes. Her impact has earned her the Harvard Business School Alumni Achievement Award, New Englander of the Year, and a place on Fortune’s “Most Powerful Women” list. Dr. Kewalramani is a passionate advocate for innovation, diversity, and the next generation of STEM leaders. Reshma Kewalramani, MD FASN #WomenInLeadership #Innovation #Healthcare #Trailblazer #STEM #Biotech #Leadership #WomenInSTEM #BreakingBarriers #Science #Inspiration #HealthTech #DiversityInTech #NextGenLeaders #vira #reels #short #shortvideo #fyp

Over the last few weeks, I have spoken to many colleagues in both pharma services and pharma companies, and many agree we are indeed in?a very tough?market environment. The broader macroeconomic trends and geopolitical uncertainty are having an effect, leading to a focus on cost reductions and efficiency gains. ? Following these conversations, I read the latest report from Medicines Discovery Catapult, highlighted in Outsourcing Pharma, with such interest. The article underscores a vital truth: our industry's capacity for innovation directly correlates with our ability to sustain investment and nurture advancements. However, the insights of the CEO of Medicines Discovery Catapult, Chris Mallow, on the importance of de-risking development industry-wide resonated with me the most.? ? Why did this resonate? It reinforces my?crucial?belief that the combined power of data, technology, AI and human expertise will help accelerate the time from research to market through effective and impactful decision-making. Furthermore, I credit the exciting possibilities of these innovations and partnerships for driving the whole sector to realize innovations and continue to enhance what we deliver and, more importantly, how we?deliver?it. ? While many feel the impacts of evolution, the great news is that the life sciences sector is resilient and ready to innovate. The great Q1 results from our clients who also practice this strategy support my beliefs, and it is a reminder that we work in one of the most fascinating and challenging arenas, which I wouldn't swap for the world.

#News: Eli Lilly and Company Gateway Labs is going global, with the U.K. government announcing today that the nation will host the first European branch of the #incubator program. The #GatewayLabs are co-working spaces for researchers that also act like accelerators. The idea is that companies or researchers that lease space have the opportunity to collaborate on mutually beneficial research and tap into Lilly’s expertise. Lilly already operates two Gateway Labs sites in South San Francisco, as well as cutting the ribbon at a new location at the Lilly Institute for Genetic Medicine in Boston's Seaport district in August. A permanent space in San Diego is expected to open next year. The U.K. will host the first Gateway Labs announced abroad as part of a 279 million pounds sterling ($364 million) investment the U.S. pharma giant is making into the U.K.’s life sciences sector. The agreement with the recently elected U.K. government—announced as part of an International Investment Summit organized by the government today—will be focused on “tackl[ing] significant health challenges,” such as obesity. Read more in Fierce Biotech ???? https://lnkd.in/e-4A6AWK